Literature DB >> 2692657

Anti-HIV-1 ADCC.

D S Tyler1, H K Lyerly, K J Weinhold.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2692657     DOI： 10.1089/aid.1989.5.557

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  17 in total

1.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

2.  Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Authors:  Margaret E Ackerman; Anne-Sophie Dugast; Elizabeth G McAndrew; Stephen Tsoukas; Anna F Licht; Darrell J Irvine; Galit Alter
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

3.  Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Peng Xiao; Jun Zhao; L Jean Patterson; Egidio Brocca-Cofano; David Venzon; Pamela A Kozlowski; Rachmat Hidajat; Thorsten Demberg; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

4.  Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.

Authors:  I Ourmanov; M Bilska; V M Hirsch; D C Montefiori
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Authors:  M Anthony Moody; Hua-Xin Liao; S Munir Alam; Richard M Scearce; M Kelly Plonk; Daniel M Kozink; Mark S Drinker; Ruijun Zhang; Shi-Mao Xia; Laura L Sutherland; Georgia D Tomaras; Ian P Giles; John C Kappes; Christina Ochsenbauer-Jambor; Tara G Edmonds; Melina Soares; Gustavo Barbero; Donald N Forthal; Gary Landucci; Connie Chang; Steven W King; Anita Kavlie; Thomas N Denny; Kwan-Ki Hwang; Pojen P Chen; Philip E Thorpe; David C Montefiori; Barton F Haynes
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

6.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 7.  Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Authors:  Margaret E Ackerman; Galit Alter
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

8.  Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

Authors:  Benjamin von Bredow; Juan F Arias; Lisa N Heyer; Brian Moldt; Khoa Le; James E Robinson; Susan Zolla-Pazner; Dennis R Burton; David T Evans
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

9.  Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Authors:  Ruth H Florese; Thorsten Demberg; Peng Xiao; LaRene Kuller; Kay Larsen; L Ebonita Summers; David Venzon; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

10.  Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

Authors:  Jun Zhao; Lilin Lai; Rama Rao Amara; David C Montefiori; Francois Villinger; Lakshmi Chennareddi; Linda S Wyatt; Bernard Moss; Harriet L Robinson
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.